Metastatic Castration-Resistant Prostate Cancer

The phase III ERA223 trial exploring radium-223 dichloride plus abiraterone acetate in patients with asymptomatic or mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer has been unblinded early. 
Read More >>
top border
top border
Featured Program
Administering Radium-223 for mCRPC
Neal D. Shore, MD, describes the logistical ease of administering radium-223 in terms of side effects and duration of the treatment. View Now >>
Highlights from the 2014 ASH Annual Meeting
Raoul S. Concepcion, MD, moderates a discussion on mCRPC with expert perspectives from Philippa J. Cheetham, MD, Kenneth M. Kernen, MD, A. Oliver Sartor, MD, Neal D. Shore, MD, and Michael E. Williams, MD. View Now

Featured Video

Hepatocellular Carcinoma (HCC):
Can We Improve Patient Survival?

Hepatocellular Carcinoma (HCC): Can We Improve Patient Survival?
Richard Finn, MD, Laura M. Kulik, MD, and Matthew S. Johnson, MD, FSIR, discuss the evolving systemic treatment paradigm for patients with advanced hepatocellular carcinoma. View now

Gina Columbus

Gina Columbus reports on the latest news in oncology in this week's edition of OncLive News Network.

Publication Bottom Border
Border Publication
x